VRDN
Viridian Therapeutics, Inc. NASDAQ Listed Jun 18, 2014$17.00
Mkt Cap $1.4B
52w Low $11.98
22.5% of range
52w High $34.29
50d MA $21.40
200d MA $24.33
P/E (TTM)
-4.0x
EV/EBITDA
-7.4x
P/B
1.6x
Debt/Equity
0.1x
ROE
-47.4%
P/FCF
-9.5x
RSI (14)
—
ATR (14)
—
Beta
1.17
50d MA
$21.40
200d MA
$24.33
Avg Volume
2.2M
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
221 Crescent Street · Waltham, MA 02453 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.90 | -1.08 | -20.0% | 29.49 | -1.6% | -0.4% | +2.6% | -0.6% | +3.1% | -2.0% | — |
| Nov 5, 2025 | AMC | -0.82 | -0.34 | +58.5% | 24.42 | +4.8% | +12.6% | +12.4% | +13.2% | +16.4% | +18.5% | — |
| Aug 6, 2025 | AMC | -1.00 | -1.00 | +0.0% | 17.20 | +0.1% | -3.9% | -4.6% | -1.8% | +4.5% | +9.6% | — |
| May 6, 2025 | AMC | -0.95 | -0.87 | +8.4% | 12.03 | +0.0% | +2.2% | +6.2% | +3.0% | +9.1% | +6.5% | — |
| Feb 27, 2025 | AMC | -1.05 | -0.81 | +22.9% | 15.29 | -0.5% | +1.6% | -5.8% | -0.4% | -0.1% | +3.9% | — |
| Nov 12, 2024 | AMC | -1.06 | -1.15 | -8.5% | 22.43 | +0.3% | +0.2% | -3.5% | -10.2% | -9.3% | -9.8% | — |
| Aug 8, 2024 | AMC | -0.89 | -1.02 | -14.6% | 15.12 | +1.0% | -0.7% | +1.1% | -2.8% | -6.2% | -1.3% | — |
| May 8, 2024 | AMC | -1.10 | -0.79 | +28.2% | 14.90 | -4.8% | -6.6% | -6.7% | -3.8% | -1.5% | -4.2% | — |
| Feb 27, 2024 | AMC | -1.00 | -1.35 | -35.0% | 19.61 | -0.5% | +2.9% | -4.6% | +1.4% | -2.9% | -7.6% | — |
| Nov 13, 2023 | AMC | -1.27 | -1.09 | +14.2% | 13.99 | +5.2% | +8.8% | +14.2% | +8.6% | +13.5% | +15.7% | — |
| Aug 8, 2023 | AMC | -1.29 | -1.27 | +1.6% | 18.75 | +0.2% | +2.7% | +4.1% | +4.6% | +5.7% | +4.3% | — |
| May 9, 2023 | AMC | -1.02 | -1.61 | -57.8% | 25.68 | -3.7% | -1.2% | -7.2% | -8.8% | -8.8% | -8.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Truist | Maintains | Buy → Buy | — | $14.68 | $14.68 | +0.0% | -2.7% | -2.4% | -3.1% | -6.5% | -8.0% |
| Apr 8 | Wedbush | Maintains | Outperform → Outperform | — | $13.96 | $14.05 | +0.6% | +3.7% | +10.2% | +7.1% | +6.0% | +8.8% |
| Apr 7 | Goldman Sachs | Maintains | Buy → Buy | — | $13.90 | $13.81 | -0.6% | +0.4% | +4.1% | +10.6% | +7.6% | +6.5% |
| Apr 7 | RBC Capital | Maintains | Outperform → Outperform | — | $13.90 | $13.81 | -0.6% | +0.4% | +4.1% | +10.6% | +7.6% | +6.5% |
| Apr 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.15 | $18.56 | -3.1% | -1.6% | -27.4% | -27.1% | -24.4% | -19.7% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $18.53 | $18.71 | +1.0% | +5.6% | +3.3% | +1.7% | -25.0% | -24.7% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $18.53 | $18.71 | +1.0% | +5.6% | +3.3% | +1.7% | -25.0% | -24.7% |
| Mar 31 | Goldman Sachs | Maintains | Buy → Buy | — | $18.53 | $18.71 | +1.0% | +5.6% | +3.3% | +1.7% | -25.0% | -24.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.53 | $18.71 | +1.0% | +5.6% | +3.3% | +1.7% | -25.0% | -24.7% |
| Mar 30 | Needham | Maintains | Buy → Buy | — | $27.39 | $17.00 | -37.9% | -32.3% | -28.6% | -30.1% | -31.2% | -49.3% |
| Mar 11 | Wedbush | Maintains | Outperform → Outperform | — | $29.19 | $28.66 | -1.8% | -2.0% | -2.7% | -1.7% | -1.4% | -2.0% |
| Feb 27 | RBC Capital | Maintains | Outperform → Outperform | — | $29.49 | $29.01 | -1.6% | -0.4% | +2.6% | -0.6% | +3.1% | -2.0% |
| Feb 4 | Needham | Maintains | Buy → Buy | — | $31.90 | $31.55 | -1.1% | -4.8% | -8.6% | -8.3% | -7.2% | -5.8% |
| Feb 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $33.20 | $33.07 | -0.4% | -3.9% | -8.5% | -12.1% | -11.9% | -10.8% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $30.57 | $30.17 | -1.3% | -0.8% | +3.9% | +6.5% | +4.6% | +10.5% |
| Dec 23 | Needham | Maintains | Buy → Buy | — | $32.47 | $32.55 | +0.2% | -1.1% | -0.6% | -1.8% | -2.9% | -4.5% |
| Dec 10 | Wedbush | Maintains | Outperform → Outperform | — | $31.80 | $31.90 | +0.3% | +2.5% | +2.4% | +1.6% | +3.9% | +3.3% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $24.42 | $25.59 | +4.8% | +12.6% | +12.4% | +13.2% | +16.4% | +18.5% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $23.15 | $22.72 | -1.9% | -2.6% | +5.5% | +18.8% | +18.5% | +19.4% |
| Oct 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.09 | $24.65 | +2.3% | -0.3% | -9.1% | -8.4% | -8.0% | -6.4% |
| Aug 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $17.20 | $17.22 | +0.1% | -3.9% | -4.6% | -1.8% | +4.5% | +9.6% |
| Aug 7 | Goldman Sachs | Maintains | Buy → Buy | — | $17.20 | $17.22 | +0.1% | -3.9% | -4.6% | -1.8% | +4.5% | +9.6% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $17.20 | $17.22 | +0.1% | -3.9% | -4.6% | -1.8% | +4.5% | +9.6% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.20 | $17.22 | +0.1% | -3.9% | -4.6% | -1.8% | +4.5% | +9.6% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $17.44 | $17.74 | +1.7% | -1.4% | -5.2% | -5.9% | -3.2% | +3.0% |
| May 20 | Needham | Maintains | Buy → Buy | — | $12.82 | $12.89 | +0.5% | +7.8% | +6.6% | +6.6% | +5.9% | +8.7% |
| May 7 | Goldman Sachs | Maintains | Buy → Buy | — | $12.03 | $12.03 | +0.0% | +2.2% | +6.2% | +3.0% | +9.1% | +6.5% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $12.03 | $12.03 | +0.0% | +2.2% | +6.2% | +3.0% | +9.1% | +6.5% |
| May 7 | Needham | Maintains | Buy → Buy | — | $12.03 | $12.03 | +0.0% | +2.2% | +6.2% | +3.0% | +9.1% | +6.5% |
| May 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.03 | $12.03 | +0.0% | +2.2% | +6.2% | +3.0% | +9.1% | +6.5% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.76 | $14.17 | +3.0% | -1.8% | -1.5% | -1.9% | -1.7% | -4.2% |
| Jan 7 | Needham | Maintains | Buy → Buy | — | $20.07 | $20.31 | +1.2% | +4.2% | -4.6% | -9.3% | -11.5% | -16.0% |
| Dec 19 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $18.93 | $18.13 | -4.2% | -1.1% | +0.5% | +3.9% | +2.0% | +4.8% |
| Dec 17 | RBC Capital | Maintains | Outperform → Outperform | — | $21.54 | $22.01 | +2.2% | -3.3% | -12.1% | -13.0% | -11.7% | -8.7% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.54 | $22.01 | +2.2% | -3.3% | -12.1% | -13.0% | -11.7% | -8.7% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.85 | $21.01 | +17.7% | +20.7% | +16.6% | +6.1% | +4.9% | +6.6% |
| Dec 5 | RBC Capital | Maintains | Outperform → Outperform | — | $19.96 | $19.90 | -0.3% | -1.7% | -1.2% | -2.2% | -3.0% | -4.9% |
| Nov 25 | Needham | Maintains | Buy → Buy | — | $20.20 | $20.89 | +3.4% | +4.1% | +8.5% | +8.3% | +6.7% | +4.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.48 | $22.44 | -0.2% | -3.7% | -10.4% | -9.5% | -10.0% | -12.0% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $22.43 | $22.50 | +0.3% | +0.2% | -3.5% | -10.2% | -9.3% | -9.8% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $23.05 | $23.51 | +2.0% | +1.0% | -1.3% | -3.8% | -6.4% | -3.3% |
| Sep 26 | BTIG | Maintains | Buy → Buy | — | $21.40 | $21.82 | +2.0% | +7.8% | +9.0% | +6.3% | +10.3% | +13.3% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $21.06 | $21.75 | +3.3% | +6.8% | +5.9% | +0.3% | +0.5% | +1.6% |
| Sep 13 | RBC Capital | Maintains | Outperform → Outperform | — | $20.70 | $21.61 | +4.4% | +6.6% | +4.2% | +2.3% | +1.7% | +8.7% |
| Sep 12 | Goldman Sachs | Maintains | Buy → Buy | — | $19.80 | $19.77 | -0.2% | +4.5% | +11.4% | +8.9% | +7.0% | +6.4% |
| Sep 11 | Needham | Maintains | Buy → Buy | — | $18.75 | $18.74 | -0.1% | +5.6% | +10.4% | +17.7% | +15.0% | +13.0% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.19 | $16.10 | +13.5% | +32.1% | +39.5% | +45.9% | +55.5% | +51.9% |
| Sep 10 | BTIG | Maintains | Buy → Buy | — | $14.19 | $16.10 | +13.5% | +32.1% | +39.5% | +45.9% | +55.5% | +51.9% |
| Aug 30 | Needham | Maintains | Buy → Buy | — | $15.00 | $15.07 | +0.5% | -2.1% | -3.5% | -1.1% | -10.2% | -6.1% |
| Aug 28 | RBC Capital | Maintains | Outperform → Outperform | — | $14.98 | $15.12 | +0.9% | -0.7% | +0.1% | -2.0% | -3.4% | -0.9% |
No insider trades available.
8-K · 2.02
!! High
Viridian Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Viridian Therapeutics reported Q1 2026 financial results, providing investors with updated operational performance and financial condition data as of March 31, 2026.
May 5
8-K · 7.01
! Medium
Viridian Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Viridian Therapeutics updated its corporate presentation to include REVEAL-2 topline data, signaling progress in clinical development that may influence investor perception of the company's pipeline.
May 5
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide a meaningful analysis because the filing summary lacks critical details about which executive changed roles, their compensation, responsibilities, or whether the change signals strategic shifts or instability.
Mar 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Positive Phase 3 data for elegrobart in thyroid eye disease supports potential regulatory approval and commercialization, significantly de-risking VRDN's pipeline and validating its rare disease strategy.
Mar 30
8-K
Viridian Therapeutics, Inc. -- 8-K Filing
Viridian Therapeutics received a June 30, 2026 PDUFA target date for veligrotug in thyroid eye disease, providing clarity on FDA review timeline for its lead therapeutic candidate.
Feb 26
Data updated apr 27, 2026 8:05am
· Source: massive.com